Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 255 entries
Sorted by: Best Match Show Resources per page
A treatment planning study comparing tomotherapy, volumetric modulated arc therapy, Sliding Window and proton therapy for low-risk prostate carcinoma.

Radiation oncology (London, England)

Scobioala S, Kittel C, Wissmann N, Haverkamp U, Channaoui M, Habibeh O, Elsayad K, Eich HT.
PMID: 27671348
Radiat Oncol. 2016 Sep 27;11(1):128. doi: 10.1186/s13014-016-0707-6.

BACKGROUND: Comparing radiation treatment plans to ascertain the optimal intensity-modulated radiation technique for low-risk prostate cancer.METHODS: Treatment plans for 20 randomly selected patients were generated using the same dose objectives. A dosimetric comparison was performed between various intensity-modulated techniques,...

Cite
Scobioala S, Kittel C, Wissmann N, et al. A treatment planning study comparing tomotherapy, volumetric modulated arc therapy, Sliding Window and proton therapy for low-risk prostate carcinoma. Radiat Oncol. 2016;11(1):128doi: 10.1186/s13014-016-0707-6.
Scobioala, S., Kittel, C., Wissmann, N., Haverkamp, U., Channaoui, M., Habibeh, O., Elsayad, K., & Eich, H. T. (2016). A treatment planning study comparing tomotherapy, volumetric modulated arc therapy, Sliding Window and proton therapy for low-risk prostate carcinoma. Radiation oncology (London, England), 11(1), 128. https://doi.org/10.1186/s13014-016-0707-6
Scobioala, Sergiu, et al. "A treatment planning study comparing tomotherapy, volumetric modulated arc therapy, Sliding Window and proton therapy for low-risk prostate carcinoma." Radiation oncology (London, England) vol. 11,1 (2016): 128. doi: https://doi.org/10.1186/s13014-016-0707-6
Scobioala S, Kittel C, Wissmann N, Haverkamp U, Channaoui M, Habibeh O, Elsayad K, Eich HT. A treatment planning study comparing tomotherapy, volumetric modulated arc therapy, Sliding Window and proton therapy for low-risk prostate carcinoma. Radiat Oncol. 2016 Sep 27;11(1):128. doi: 10.1186/s13014-016-0707-6. PMID: 27671348; PMCID: PMC5037612.
Copy Download .nbib Format: NLM
Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts.

BMC research notes

Vallo S, Michaelis M, Gust KM, Black PC, Rothweiler F, Kvasnicka HM, Blaheta RA, Brandt MP, Wezel F, Haferkamp A, Cinatl J.
PMID: 27677700
BMC Res Notes. 2016 Sep 27;9(1):454. doi: 10.1186/s13104-016-2256-3.

BACKGROUND: Systemic chemotherapy with gemcitabine and cisplatin is standard of care for patients with metastatic urothelial bladder cancer. However, resistance formation is common after initial response. The protein Src is known as a proto-oncogene, which is overexpressed in various...

Cite
Vallo S, Michaelis M, Gust KM, et al. Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts. BMC Res Notes. 2016;9(1):454doi: 10.1186/s13104-016-2256-3.
Vallo, S., Michaelis, M., Gust, K. M., Black, P. C., Rothweiler, F., Kvasnicka, H. M., Blaheta, R. A., Brandt, M. P., Wezel, F., Haferkamp, A., & Cinatl, J. (2016). Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts. BMC research notes, 9(1), 454. https://doi.org/10.1186/s13104-016-2256-3
Vallo, Stefan, et al. "Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts." BMC research notes vol. 9,1 (2016): 454. doi: https://doi.org/10.1186/s13104-016-2256-3
Vallo S, Michaelis M, Gust KM, Black PC, Rothweiler F, Kvasnicka HM, Blaheta RA, Brandt MP, Wezel F, Haferkamp A, Cinatl J. Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts. BMC Res Notes. 2016 Sep 27;9(1):454. doi: 10.1186/s13104-016-2256-3. PMID: 27677700; PMCID: PMC5039786.
Copy Download .nbib Format: NLM
Qualitative Twitter analysis of participants, tweet strategies, and tweet content at a major urologic conference.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Borgmann H, Woelm JH, Merseburger A, Nestler T, Salem J, Brandt MP, Haferkamp A, Loeb S.
PMID: 26977205
Can Urol Assoc J. 2016 Jan-Feb;10(1):39-44. doi: 10.5489/cuaj.3322.

INTRODUCTION: The microblogging social media platform Twitter is increasingly being adopted in the urologic field. We aimed to analyze participants, tweet strategies, and tweet content of the Twitter discussion at a urologic conference.METHODS: A comprehensive analysis of the Twitter...

Cite
Borgmann H, Woelm JH, Merseburger A, et al. Qualitative Twitter analysis of participants, tweet strategies, and tweet content at a major urologic conference. Can Urol Assoc J. 2016;10(1):39-44doi: 10.5489/cuaj.3322.
Borgmann, H., Woelm, J. H., Merseburger, A., Nestler, T., Salem, J., Brandt, M. P., Haferkamp, A., & Loeb, S. (2016). Qualitative Twitter analysis of participants, tweet strategies, and tweet content at a major urologic conference. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 10(1), 39-44. https://doi.org/10.5489/cuaj.3322
Borgmann, Hendrik, et al. "Qualitative Twitter analysis of participants, tweet strategies, and tweet content at a major urologic conference." Canadian Urological Association journal = Journal de l'Association des urologues du Canada vol. 10,1 (2016): 39-44. doi: https://doi.org/10.5489/cuaj.3322
Borgmann H, Woelm JH, Merseburger A, Nestler T, Salem J, Brandt MP, Haferkamp A, Loeb S. Qualitative Twitter analysis of participants, tweet strategies, and tweet content at a major urologic conference. Can Urol Assoc J. 2016 Jan-Feb;10(1):39-44. doi: 10.5489/cuaj.3322. PMID: 26977205; PMCID: PMC4771557.
Copy Download .nbib Format: NLM
Evaluation of TKTL1 as a biomarker in serum of prostate cancer patients.

Central European journal of urology

Tsaur I, Thurn K, Juengel E, Oppermann E, Nelson K, Thomas C, Bartsch G, Oremek GM, Haferkamp A, Rubenwolf P, Blaheta RA.
PMID: 27729989
Cent European J Urol. 2016;69(3):247-251. doi: 10.5173/ceju.2016.820. Epub 2016 Jun 30.

INTRODUCTION: Monocyte associated transketolase-like 1 (TKTL1) as a cancer biomarker has become popular with alternative practitioners, but plays no role in conventional medicine. This investigation evaluates the potential of serum TKTL1 as a biomarker for prostate cancer.MATERIAL AND METHODS:...

Cite
Tsaur I, Thurn K, Juengel E, et al. Evaluation of TKTL1 as a biomarker in serum of prostate cancer patients. Cent European J Urol. 2016;69(3):247-251doi: 10.5173/ceju.2016.820.
Tsaur, I., Thurn, K., Juengel, E., Oppermann, E., Nelson, K., Thomas, C., Bartsch, G., Oremek, G. M., Haferkamp, A., Rubenwolf, P., & Blaheta, R. A. (2016). Evaluation of TKTL1 as a biomarker in serum of prostate cancer patients. Central European journal of urology, 69(3), 247-251. https://doi.org/10.5173/ceju.2016.820
Tsaur, Igor, et al. "Evaluation of TKTL1 as a biomarker in serum of prostate cancer patients." Central European journal of urology vol. 69,3 (2016): 247-251. doi: https://doi.org/10.5173/ceju.2016.820
Tsaur I, Thurn K, Juengel E, Oppermann E, Nelson K, Thomas C, Bartsch G, Oremek GM, Haferkamp A, Rubenwolf P, Blaheta RA. Evaluation of TKTL1 as a biomarker in serum of prostate cancer patients. Cent European J Urol. 2016;69(3):247-251. doi: 10.5173/ceju.2016.820. Epub 2016 Jun 30. PMID: 27729989; PMCID: PMC5057049.
Copy Download .nbib Format: NLM
Valproate inhibits colon cancer growth through cell cycle modification in vivo and in vitro.

Experimental and therapeutic medicine

Strey CW, Schamell L, Oppermann E, Haferkamp A, Bechstein WO, Blaheta RA.
PMID: 22977502
Exp Ther Med. 2011 Mar;2(2):301-307. doi: 10.3892/etm.2011.202. Epub 2011 Jan 20.

Valproate (VPA) is a well-characterized histone deacetylase inhibitor with anti-neoplastic properties. We analyzed the growth blocking effects and the molecular mode of action of this compound in colorectal cancer cells in vitro and in vivo. Caco-2, SW-480, CX-1 or...

Cite
Strey CW, Schamell L, Oppermann E, et al. Valproate inhibits colon cancer growth through cell cycle modification in vivo and in vitro. Exp Ther Med. 2011;2(2):301-307doi: 10.3892/etm.2011.202.
Strey, C. W., Schamell, L., Oppermann, E., Haferkamp, A., Bechstein, W. O., & Blaheta, R. A. (2011). Valproate inhibits colon cancer growth through cell cycle modification in vivo and in vitro. Experimental and therapeutic medicine, 2(2), 301-307. https://doi.org/10.3892/etm.2011.202
Strey, Christoph W, et al. "Valproate inhibits colon cancer growth through cell cycle modification in vivo and in vitro." Experimental and therapeutic medicine vol. 2,2 (2011): 301-307. doi: https://doi.org/10.3892/etm.2011.202
Strey CW, Schamell L, Oppermann E, Haferkamp A, Bechstein WO, Blaheta RA. Valproate inhibits colon cancer growth through cell cycle modification in vivo and in vitro. Exp Ther Med. 2011 Mar;2(2):301-307. doi: 10.3892/etm.2011.202. Epub 2011 Jan 20. PMID: 22977502; PMCID: PMC3440661.
Copy Download .nbib Format: NLM
Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics.

Translational oncology

Vallo S, Michaelis M, Rothweiler F, Bartsch G, Gust KM, Limbart DM, Rödel F, Wezel F, Haferkamp A, Cinatl J.
PMID: 26055179
Transl Oncol. 2015 Jun;8(3):210-6. doi: 10.1016/j.tranon.2015.04.002.

Combination chemotherapy with gemcitabine and cisplatin in patients with metastatic urothelial cancer of the bladder frequently results in the development of acquired drug resistance. Availability of cell culture models with acquired resistance could help to identify candidate treatments for...

Cite
Vallo S, Michaelis M, Rothweiler F, et al. Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics. Transl Oncol. 2015;8(3):210-6doi: 10.1016/j.tranon.2015.04.002.
Vallo, S., Michaelis, M., Rothweiler, F., Bartsch, G., Gust, K. M., Limbart, D. M., Rödel, F., Wezel, F., Haferkamp, A., & Cinatl, J. (2015). Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics. Translational oncology, 8(3), 210-6. https://doi.org/10.1016/j.tranon.2015.04.002
Vallo, Stefan, et al. "Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics." Translational oncology vol. 8,3 (2015): 210-6. doi: https://doi.org/10.1016/j.tranon.2015.04.002
Vallo S, Michaelis M, Rothweiler F, Bartsch G, Gust KM, Limbart DM, Rödel F, Wezel F, Haferkamp A, Cinatl J. Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics. Transl Oncol. 2015 Jun;8(3):210-6. doi: 10.1016/j.tranon.2015.04.002. PMID: 26055179; PMCID: PMC4487788.
Copy Download .nbib Format: NLM
The interactive web-based program MSmonitor for self-management and multidisciplinary care in multiple sclerosis: concept, content, and pilot results.

Patient preference and adherence

Jongen PJ, Sinnige LG, van Geel BM, Verheul F, Verhagen WI, van der Kruijk RA, Haverkamp R, Schrijver HM, Baart JC, Visser LH, Arnoldus EP, Gilhuis HJ, Pop P, Booy M, Lemmens W, Donders R, Kool A, van Noort E.
PMID: 26715841
Patient Prefer Adherence. 2015 Dec 11;9:1741-50. doi: 10.2147/PPA.S93783. eCollection 2015.

BACKGROUND: There is a growing need to offer persons with multiple sclerosis (PwMS) possibilities for self-management and to integrate multidisciplinary health data. In 2009-2014 we developed a patient-reported outcome based, interactive, web-based program (MSmonitor) for (self-)monitoring, self-management and integrated,...

Cite
Jongen PJ, Sinnige LG, van Geel BM, et al. The interactive web-based program MSmonitor for self-management and multidisciplinary care in multiple sclerosis: concept, content, and pilot results. Patient Prefer Adherence. 2015;9:1741-50doi: 10.2147/PPA.S93783.
Jongen, P. J., Sinnige, L. G., van Geel, B. M., Verheul, F., Verhagen, W. I., van der Kruijk, R. A., Haverkamp, R., Schrijver, H. M., Baart, J. C., Visser, L. H., Arnoldus, E. P., Gilhuis, H. J., Pop, P., Booy, M., Lemmens, W., Donders, R., Kool, A., & van Noort, E. (2015). The interactive web-based program MSmonitor for self-management and multidisciplinary care in multiple sclerosis: concept, content, and pilot results. Patient preference and adherence, 91741-50. https://doi.org/10.2147/PPA.S93783
Jongen, Peter Joseph, et al. "The interactive web-based program MSmonitor for self-management and multidisciplinary care in multiple sclerosis: concept, content, and pilot results." Patient preference and adherence vol. 9 (2015): 1741-50. doi: https://doi.org/10.2147/PPA.S93783
Jongen PJ, Sinnige LG, van Geel BM, Verheul F, Verhagen WI, van der Kruijk RA, Haverkamp R, Schrijver HM, Baart JC, Visser LH, Arnoldus EP, Gilhuis HJ, Pop P, Booy M, Lemmens W, Donders R, Kool A, van Noort E. The interactive web-based program MSmonitor for self-management and multidisciplinary care in multiple sclerosis: concept, content, and pilot results. Patient Prefer Adherence. 2015 Dec 11;9:1741-50. doi: 10.2147/PPA.S93783. eCollection 2015. PMID: 26715841; PMCID: PMC4685885.
Copy Download .nbib Format: NLM
A Challenge for a Male Noctuid Moth? Discerning the Female Sex Pheromone against the Background of Plant Volatiles.

Frontiers in physiology

Badeke E, Haverkamp A, Hansson BS, Sachse S.
PMID: 27199761
Front Physiol. 2016 Apr 25;7:143. doi: 10.3389/fphys.2016.00143. eCollection 2016.

Finding a partner is an essential task for members of all species. Like many insects, females of the noctuid moth Heliothis virescens release chemical cues consisting of a species-specific pheromone blend to attract conspecific males. While tracking these blends,...

Cite
Badeke E, Haverkamp A, Hansson BS, et al. A Challenge for a Male Noctuid Moth? Discerning the Female Sex Pheromone against the Background of Plant Volatiles. Front Physiol. 2016;7:143doi: 10.3389/fphys.2016.00143.
Badeke, E., Haverkamp, A., Hansson, B. S., & Sachse, S. (2016). A Challenge for a Male Noctuid Moth? Discerning the Female Sex Pheromone against the Background of Plant Volatiles. Frontiers in physiology, 7143. https://doi.org/10.3389/fphys.2016.00143
Badeke, Elisa, et al. "A Challenge for a Male Noctuid Moth? Discerning the Female Sex Pheromone against the Background of Plant Volatiles." Frontiers in physiology vol. 7 (2016): 143. doi: https://doi.org/10.3389/fphys.2016.00143
Badeke E, Haverkamp A, Hansson BS, Sachse S. A Challenge for a Male Noctuid Moth? Discerning the Female Sex Pheromone against the Background of Plant Volatiles. Front Physiol. 2016 Apr 25;7:143. doi: 10.3389/fphys.2016.00143. eCollection 2016. PMID: 27199761; PMCID: PMC4843018.
Copy Download .nbib Format: NLM
Low-dose dexamethasone during arthroplasty: What do we know about the risks?.

EFORT open reviews

Wegener JT, Kraal T, Stevens MF, Hollmann MW, Kerkhoffs GMMJ, Haverkamp D.
PMID: 28461961
EFORT Open Rev. 2017 Mar 13;1(8):303-309. doi: 10.1302/2058-5241.1.000039. eCollection 2016 Aug.

Dexamethasone is commonly applied during arthroplasty to control post-operative nausea and vomiting (PONV). However, conflicting views of orthopaedic surgeons and anaesthesiologists regarding the use of dexamethasone raise questions about risks of impaired wound healing and surgical site infections (SSI).The...

Cite
Wegener JT, Kraal T, Stevens MF, et al. Low-dose dexamethasone during arthroplasty: What do we know about the risks?. EFORT Open Rev. 2017;1(8):303-309doi: 10.1302/2058-5241.1.000039.
Wegener, J. T., Kraal, T., Stevens, M. F., Hollmann, M. W., Kerkhoffs, G. M. M. J., & Haverkamp, D. (2016). Low-dose dexamethasone during arthroplasty: What do we know about the risks?. EFORT open reviews, 1(8), 303-309. https://doi.org/10.1302/2058-5241.1.000039
Wegener, Jessica T, et al. "Low-dose dexamethasone during arthroplasty: What do we know about the risks?." EFORT open reviews vol. 1,8 (2016): 303-309. doi: https://doi.org/10.1302/2058-5241.1.000039
Wegener JT, Kraal T, Stevens MF, Hollmann MW, Kerkhoffs GMMJ, Haverkamp D. Low-dose dexamethasone during arthroplasty: What do we know about the risks?. EFORT Open Rev. 2017 Mar 13;1(8):303-309. doi: 10.1302/2058-5241.1.000039. eCollection 2016 Aug. PMID: 28461961; PMCID: PMC5367537.
Copy Download .nbib Format: NLM
Correction: Psychological Distress in the Hospital Setting: A Comparison between Native Dutch and Immigrant Patients.

PloS one

Haverkamp GL, Torensma B, Vergouwen AC, Honig A.
PMID: 27428263
PLoS One. 2016 Jul 18;11(7):e0159697. doi: 10.1371/journal.pone.0159697. eCollection 2016.

[This corrects the article DOI: 10.1371/journal.pone.0130961.].

Cite
Haverkamp GL, Torensma B, Vergouwen AC, et al. Correction: Psychological Distress in the Hospital Setting: A Comparison between Native Dutch and Immigrant Patients. PLoS One. 2016;11(7):e0159697doi: 10.1371/journal.pone.0159697.
Haverkamp, G. L., Torensma, B., Vergouwen, A. C., & Honig, A. (2016). Correction: Psychological Distress in the Hospital Setting: A Comparison between Native Dutch and Immigrant Patients. PloS one, 11(7), e0159697. https://doi.org/10.1371/journal.pone.0159697
Haverkamp, Gertrud L G, et al. "Correction: Psychological Distress in the Hospital Setting: A Comparison between Native Dutch and Immigrant Patients." PloS one vol. 11,7 (2016): e0159697. doi: https://doi.org/10.1371/journal.pone.0159697
Haverkamp GL, Torensma B, Vergouwen AC, Honig A. Correction: Psychological Distress in the Hospital Setting: A Comparison between Native Dutch and Immigrant Patients. PLoS One. 2016 Jul 18;11(7):e0159697. doi: 10.1371/journal.pone.0159697. eCollection 2016. PMID: 27428263; PMCID: PMC4948876.
Copy Download .nbib Format: NLM
"Hot standards" for the thermoacidophilic archaeon Sulfolobus solfataricus.

Extremophiles : life under extreme conditions

Zaparty M, Esser D, Gertig S, Haferkamp P, Kouril T, Manica A, Pham TK, Reimann J, Schreiber K, Sierocinski P, Teichmann D, van Wolferen M, von Jan M, Wieloch P, Albers SV, Driessen AJ, Klenk HP, Schleper C, Schomburg D, van der Oost J, Wright PC, Siebers B.
PMID: 19802714
Extremophiles. 2010 Jan;14(1):119-42. doi: 10.1007/s00792-009-0280-0. Epub 2009 Oct 04.

Within the archaea, the thermoacidophilic crenarchaeote Sulfolobus solfataricus has become an important model organism for physiology and biochemistry, comparative and functional genomics, as well as, more recently also for systems biology approaches. Within the Sulfolobus Systems Biology ("SulfoSYS")-project the...

Cite
Zaparty M, Esser D, Gertig S, et al. "Hot standards" for the thermoacidophilic archaeon Sulfolobus solfataricus. Extremophiles. 2009;14(1):119-42doi: 10.1007/s00792-009-0280-0.
Zaparty, M., Esser, D., Gertig, S., Haferkamp, P., Kouril, T., Manica, A., Pham, T. K., Reimann, J., Schreiber, K., Sierocinski, P., Teichmann, D., van Wolferen, M., von Jan, M., Wieloch, P., Albers, S. V., Driessen, A. J., Klenk, H. P., Schleper, C., Schomburg, D., van der Oost, J., Wright, P. C., & Siebers, B. (2010). "Hot standards" for the thermoacidophilic archaeon Sulfolobus solfataricus. Extremophiles : life under extreme conditions, 14(1), 119-42. https://doi.org/10.1007/s00792-009-0280-0
Zaparty, Melanie, et al. ""Hot standards" for the thermoacidophilic archaeon Sulfolobus solfataricus." Extremophiles : life under extreme conditions vol. 14,1 (2010): 119-42. doi: https://doi.org/10.1007/s00792-009-0280-0
Zaparty M, Esser D, Gertig S, Haferkamp P, Kouril T, Manica A, Pham TK, Reimann J, Schreiber K, Sierocinski P, Teichmann D, van Wolferen M, von Jan M, Wieloch P, Albers SV, Driessen AJ, Klenk HP, Schleper C, Schomburg D, van der Oost J, Wright PC, Siebers B. "Hot standards" for the thermoacidophilic archaeon Sulfolobus solfataricus. Extremophiles. 2010 Jan;14(1):119-42. doi: 10.1007/s00792-009-0280-0. Epub 2009 Oct 04. PMID: 19802714; PMCID: PMC2797409.
Copy Download .nbib Format: NLM
Glycinergic transmission in the Mammalian retina.

Frontiers in molecular neuroscience

Wässle H, Heinze L, Ivanova E, Majumdar S, Weiss J, Harvey RJ, Haverkamp S.
PMID: 19924257
Front Mol Neurosci. 2009 Jul 09;2:6. doi: 10.3389/neuro.02.006.2009. eCollection 2009.

Glycine and gamma-aminobutyric acid (GABA) are the major inhibitory neurotransmitters in the retina. Approximately half of the amacrine cells release glycine at their synapses with bipolar, other amacrine, and ganglion cells. Glycinergic amacrine cells are small-field amacrine cells with...

Cite
Wässle H, Heinze L, Ivanova E, et al. Glycinergic transmission in the Mammalian retina. Front Mol Neurosci. 2009;2:6doi: 10.3389/neuro.02.006.2009.
Wässle, H., Heinze, L., Ivanova, E., Majumdar, S., Weiss, J., Harvey, R. J., & Haverkamp, S. (2009). Glycinergic transmission in the Mammalian retina. Frontiers in molecular neuroscience, 26. https://doi.org/10.3389/neuro.02.006.2009
Wässle, Heinz, et al. "Glycinergic transmission in the Mammalian retina." Frontiers in molecular neuroscience vol. 2 (2009): 6. doi: https://doi.org/10.3389/neuro.02.006.2009
Wässle H, Heinze L, Ivanova E, Majumdar S, Weiss J, Harvey RJ, Haverkamp S. Glycinergic transmission in the Mammalian retina. Front Mol Neurosci. 2009 Jul 09;2:6. doi: 10.3389/neuro.02.006.2009. eCollection 2009. PMID: 19924257; PMCID: PMC2777502.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 255 entries